Categorynews

$16+ Billion Antihyperlipidemic Drugs Market (2019 to 2026) – Global Opportunity Analysis and Industry Forecast – ResearchAndMarkets.com

March 18, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2019-2026” report has been added to ResearchAndMarkets.com’s offering.

The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

The factors that contribute for the growth of the market include a surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, a surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.

Key benefits for stakeholders

  • This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

List of key players profiled in the report:

  • Boehringer Ingelheim GmbH
  • Merck KGaA
  • Johnson and Johnson
  • Bayer AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • AstraZeneca plc,

Key findings of the study:

  1. Statins occupied one-third share of the global antihyperlipidemic drugs market in 2018.
  2. The PCSK9 inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
  3. The cholesterol absorption inhibitors segment accounted for more than one-fourth share of the market in 2018.
  4. Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Key Topics Covered:

Chapter 1: Introduction

1.1. Report Description

1.2. Key Market Segments

1.2.1. List of Key Players Profiled In The Report

1.3. Research Methodology

1.3.1. Primary Research

1.3.2. Secondary Research

1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study

2.2. CXO Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Top Player Positioning

3.2.1. Top Investment Pockets

3.3. Key Forces Shaping Antihyperlipidemic Industry/Market

3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Presence of Guidelines Recommending The Use of Statins

3.4.1.2. Surge In Healthcare Expenditure Worldwide

3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe

3.4.2. Restraint

3.4.2.1. Upcoming Patent Expirations of Drugs

3.4.3. Opportunity

3.4.3.1. High Growth Potential In Developing Economies

3.4.4. Impact Analyses

Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Statins

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis By Country

4.3. Bile Acid Sequestrants

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis By Country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis By Country

4.5. Fibric Acid Derivatives

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis By Country

4.6. Pcsk9 Inhibitors

4.6.1. Key Market Trends, Growth Factors, And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis By Country

4.7. Combination

4.7.1. Key Market Trends, Growth Factors, And Opportunities

4.7.2. Market Size And Forecast, By Region

4.7.3. Market Analysis By Country

4.8. Others

4.8.1. Key Market Trends, Growth Factors, And Opportunities

4.8.2. Market Size And Forecast, By Region

4.8.3. Market Analysis By Country

Chapter 5: Antihyperlipidemic Drugs Market, By Region

5.1. Overview

5.2. North America

5.3. Europe

5.4. Asia-Pacific

5.5. LAMEA

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.2. Amgen Inc.

6.3. AstraZeneca Plc

6.4. Bristol-Myers Squibb Company

6.5. Daiichi Sankyo Company, Limited

6.6. Dr. Reddy’S Laboratories Ltd

6.7. Merck & Co., Inc

6.8. Mylan N.V

6.9. Pfizer Inc.

6.10. Sanofi S.A.

For more information about this report visit https://www.researchandmarkets.com/r/gblcfv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900